Real world efficacy of 12 weeks sofosbuvir, daclastivir with ribavirin among cirrhotic pre and post-transplant genotype 3 hepatitis C infected patients von Schmidt-Martin, D, Bufton, S, Roberts, M, Rye, K, Singhal, S, Eldred, S, Perry, I, Corbett, C, Unitt, E, Wood, V, Dillon, H, Haydon, G.H, Mutimer, D, Elsharkawy, A.M

Volltext

THU-252 - Real world efficacy of 12 weeks sofosbuvir, daclastivir with ribavirin among cirrhotic pre and post-transplant genotype 3 hepatitis C infected patients von Schmidt-Martin, D., Bufton, S., Roberts, M., Rye, K., Singhal, S., Eldred, S., Perry, I., Corbett, C., Unitt, E., Wood, V., Dillon, H., Haydon, G.H., Mutimer, D., Elsharkawy, A.M.

Volltext

156 Dose of tacrolimus required to maintain therapeutic levels decerases post liver transplant in hepatitis C (HCV) recipients von Oo, Y.H., Dudley, T., Nightingale, P.G., Haydon, G.H., Mutimer, D.J.

Volltext

The effect of extracorporeal albumin dialysis (MARS) on pathophysiological parameters in patients with acute liver failure (ALF) von Lai, W.K., Haydon, G.H., Mutimer, D., Murphy, N.

Volltext

The effect of serum from liver cancer patients on the growth and function of primary and immortalised hepatocytes von Grant, M H, Rodgers, E H, Anderson, K, Haydon, G H, Hayes, P C

Volltext